Skip to main content
spacbrain

Tango Therapeutics

Closed (deSPAC)

Health Care · oncology therapeutics development

What it is
Therapeutics Tango Therapeutics is a biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer
What it’s doing now
Merging with BCTG Acquisition Corp. (BCTG) — closed (despac).
What you should know
The deal carries a $300M minimum-cash condition — heavy redemptions can break it.

The business, per its filings

SEC primary

Therapeutics Tango Therapeutics is a biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. This includes expanding the universe of precision oncology targets into novel areas such as tumor suppressor gene loss and their contribution to the ability of cancer cells to evade immune cell killing. For more information, please visit www.tangotx.com.

Source: S-4/A, accession 0001213900-21-037131

What the company says about itself

Web research — not audited

Tango Therapeutics leverages the principle of synthetic lethality to develop medicines that take direct aim at specific tumors. Using an approach that starts and ends with patients, they are expanding the reach of genetically targeted therapies.

Markets:
Biotechnology | Pharmaceuticals
What our web check found

[WEB-INTEL 2026-08-26] 4 finding(s) · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Tango Therapeutics Announces Proposed $500 Million Public" [https://ir.tangotx.com/news-releases/news-release-details/tango-therapeutics-announces-proposed-500-million-public] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "$225 Million Financing … expected to be approximately $210 million." [https://www.globenewswire.com/news-release/2025/10/23/3171915/0/en/tango-therapeutics-announces-225-million-financing.html] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Leading institutional investors commit $186 million through a common stock private investment in public equity (“PIPE”) led by Boxer Capital." [https://ir.tangotx.com/news-releases/news-release-details/tango-therapeutics-and-bctg-acquisition-corp-announce-merger] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Tango Therapeutics is going public through a $353 million SPAC deal" [https://www.statnews.com/2021/04/14/tango-therapeutics-biotech-spac/]

Source: https://www.tangotx.com/ · captured Aug 26, 2026 · marketing claims are reported as claims, never merged into the filed figures above.

The deal it’s entering

Tango Therapeutics is merging with BCTG Acquisition Corp. (BCTG) currently marked Closed (deSPAC).

Headline equity value—
PIPE≈ $186M · unsourced
Minimum cash to close$300M

Structure per SEC accession(s) 0001213900-21-022195. How to read these numbers: headline vs effective valuation · what a definitive agreement commits

What exactly is being valued, and at what

Common questions

Is Tango Therapeutics going public?

Tango Therapeutics has an approved merger with the SPAC BCTG Acquisition Corp. (BCTG). Deal status: Closed (deSPAC).

Does Tango Therapeutics have revenue?

The filings we've parsed don't state a usable revenue figure yet; this profile is updated as new documents land.

Educational content, not investment advice.

Other health care deals